ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Novus Therapeutics Inc

Novus Therapeutics Inc (NVUS)

14.60
0.00
( 0.00% )
Updated: 18:00:00

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
14.60
Bid
14.65
Ask
21.00
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
14.60
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
24,198,000
Dividend Yield
-
PE Ratio
-2.66
Earnings Per Share (EPS)
-1.67
Revenue
-
Net Profit
-40.33M

About Novus Therapeutics Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
-

NVUS Latest News

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic ...

Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular...

Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of...

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences

Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant...

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

Acquisition includes lead clinical-stage compound AT-1501, a next generation anti-CD40L antibody, in development for organ and cellular transplantation, autoimmune diseases, and neurodegenerative...

Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...

Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced...

Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference

Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire IRVINE, Calif., Nov. 21, 2017 IRVINE, Calif., Nov. 21, 2017 /PRNewswire/ -- Novus Therapeutics...

Novus Therapeutics Reports Third Quarter 2017 Results

Novus Therapeutics Reports Third Quarter 2017 Results PR Newswire IRVINE, California, Nov. 8, 2017 IRVINE, California, Nov. 8, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a...

Novus Therapeutics Reports Third Quarter 2017 Results

Novus Therapeutics Reports Third Quarter 2017 Results PR Newswire IRVINE, Calif., Nov. 8, 2017 IRVINE, Calif., Nov. 8, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a development...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PALIPalisade Bio Inc
US$ 2.5312
(80.80%)
47.73M
TRVITrevi Therapeutics Inc
US$ 4.0092
(61.01%)
38.07M
TRUGTruGolf Holdings Inc
US$ 0.7096
(60.91%)
42.43M
LAESSEALSQ Corporation
US$ 1.6894
(46.90%)
136.92M
GOSSGossamer Bio Inc
US$ 0.9989
(40.18%)
8.68M
SPGCSacks Parente Golf Inc
US$ 0.2962
(-78.84%)
10.22M
KROSKeros Therapeutics Inc
US$ 16.3025
(-76.25%)
6.21M
TFFPTFF Pharmaceuticals Inc
US$ 0.0739
(-54.58%)
2.68M
SFHGSamfine Creation Holdings Group Ltd
US$ 1.45
(-52.46%)
3.42M
AVGRAvinger Inc
US$ 0.414749
(-49.42%)
446.79k
LAESSEALSQ Corporation
US$ 1.6839
(46.43%)
136.95M
CDTConduit Pharmaceuticals Inc
US$ 0.0886
(0.34%)
83.65M
GOEVCanoo Inc
US$ 0.1781
(37.00%)
72.56M
AMPGAmplitech Group Inc
US$ 2.59
(34.20%)
53.77M
RGTIRigetti Computing Inc
US$ 7.525
(1.96%)
52.11M

Discussion

View Full Feed
wadegarret wadegarret 2 minutes ago
FEIM bid/ask spread is 2.5%

How can anyone make money is stocks where you have to pay 2.5% getting in and out if you want in or out quickly ?
That means, you're a 5% loser to begin with ! Many of the micro cap stocks touted on this board have bid/ask spreads even higher
Slojab Slojab 2 minutes ago
And there's that "soon" again.

Sep 3
GMSacha Inchi $QEDN submitted the required documents to OTC. $QEDN should be back to pink current soon
QEDN
ace65 ace65 2 minutes ago
ATWT ..nothing on ask great revs.r/m awhile back.
ATWT
Momentum_Scalper Momentum_Scalper 3 minutes ago
Or 60s lol
BCDS
Scott999 Scott999 3 minutes ago
-$5,283,000 shareholder equity as of Sept 30th. They lost over $6,000,000 last quarter so by now with a bit more than half a month to go in this quarter, they should be hitting -$10,000,000 in shareholder equity.

Next stop…the pinks.
PLUR
bobby1151 bobby1151 3 minutes ago
NO way Jose - NO reverse merger between Bioelectronics Corp a public traded corp & VM also a public traded corp.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
BIEL
Strukture Strukture 3 minutes ago
AXXA Weekly & MTHLY Parabolic SAR just flipped bullish EVERYTIME since 2018 it has done this (2x) it has run min 1800% not saying it will do that here BUT a weekly/Mthly PSAR flip is a very bullish trigger
https://www.tradingview.com/x/oinIKrBv/
AXXA
threewheeler threewheeler 3 minutes ago
FDA approval enough said, not going to spoon feed a basher acting like a newbie
KRTL
Watts Watt Watts Watt 3 minutes ago
More like a millstone.
LQMT
TRUSTUNITS1000000 TRUSTUNITS1000000 3 minutes ago
Wonder sell now, buy lower
FMNJ
Shareing is winning Shareing is winning 4 minutes ago
December 12 2024 - 7:30AM

Alert
Print
Share On Facebook

Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that the Company successfully integrated Recraft AI into th
GXAI
Longstrongsilver Longstrongsilver 4 minutes ago
🤦‍♂️
AZRH
phillymike phillymike 4 minutes ago
LOL!

WLAN
WLAN
TRUSTUNITS1000000 TRUSTUNITS1000000 4 minutes ago
0.0001
FMNJ
fwb fwb 4 minutes ago
If you think PLTR is going DOWN soon, SELL your SHARES now.
SMCI
jimr1717 jimr1717 4 minutes ago
So are you saying that not only did the company lie about being QB listed they also lied about adding 42 million shares?
Interesting thought
ATMH
TRUSTUNITS1000000 TRUSTUNITS1000000 4 minutes ago
0.0011
FMNJ
thesmallguy thesmallguy 4 minutes ago
Losing faith here.
ASII
Helter Skelter Helter Skelter 4 minutes ago
Gathering a few 2.42s here...$PALI
PALI
Golden Cross Golden Cross 4 minutes ago
$ILLR Triller Could Have META-Like Move In It!

META/Facebook Went From $38 2012 IPO Price to a high of $595! Early doubters saw shares drop below $18, but look at it now! 💥

Believe in your vision. The journey might be rough, but persistence pays off! 💪✨
ILLR
skyrocketinsight skyrocketinsight 4 minutes ago
I rescinded all of my complaints with the SEC
MIKP
Doc logic Doc logic 4 minutes ago
iclight,

So you say!; ). Convergence suggests otherwise in that Flaskworks is needed for the business model to really work to be a commercially viable partner ready expansion model. Proximity of Flaskworks readiness to initial approval has always been the bump in the road Mr. Neil
NWBO
TRUSTUNITS1000000 TRUSTUNITS1000000 4 minutes ago
A while back thought multiple pennies
VGID
RuudSaltis RuudSaltis 5 minutes ago
I mailed the BOD already early this year that the management had to restructured. A tech guy responsible for deal making is rarely a good match. Also the communication marketing and PR were totally amateurism. I hope that the new management is ready to execute commercialisation quickly! It seems so.
LWLG
FeMike FeMike 5 minutes ago
Dave Innes can answer that and the company can PR it. If the answer was "they are done" it would be good news. They would PR it.

Well, this is just not true.

Look at the latest Q for evidence that they have a slew of good news they could PR but are choosing not to. Com
NWBO

Your Recent History

Delayed Upgrade Clock